Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 3.
doi: 10.1007/s12094-025-04102-w. Online ahead of print.

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025)

Jose Angel Garcia-Saenz  1 , Isabel Blancas Lopez-Barajas  2 , Isabel Echavarria  3 , Carmen Hinojo Gonzalez  4 , Mireia Margeli Vila  5 , Fernando Moreno Antón  6 , Sonia Pernas  7 , Teresa Ramon Y Cajal  8 , Nuria Ribelles  9 , Meritxell Bellet Ezquerra  10
Affiliations

SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025)

Jose Angel Garcia-Saenz et al. Clin Transl Oncol. .

Abstract

Advanced breast cancer represents a challenge for patients and physicians due to its dynamic genomic changes, which are associated with resistance to treatments. The main goals of treatment in advanced breast cancer are to improve patient quality of life and to increase patient survival. This is achieved using the most appropriate sequence of treatments based on knowledge of the natural history of the disease. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medical management of advanced breast cancer.

Keywords: Advanced breast cancer; Anti-HER2 therapy; Endocrine therapy; Guidelines; Metastatic breast cancer.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: Jose Angel Garcia‑Saenz has received speaker fees and has attended an advisory board for Novartis, Lilly, Daiichi Sankyo, and Gilead; has attended an advisory board for AstraZeneca, Pierre Fabre, and EISAI; has received a grant from Seagen; has received speaker fees from Roche, Asofarma, and Exact Sciences; and has received a grant and has attended an advisory board for Stemline Menarini. Isabel Blancas Lopez-Barajas has received speaker fees and grants and has attended an advisory board for Roche, Lilly, and AstraZeneca; has received speaker fees and has attended an advisory board for Novartis, Celgene, Eisai, Pierre Fabre, BMS, Daiichi Sankyo, Grünenthal, Seagen, and Veracyte; and has received a grant from Agendia. Isabel Echavarria has received speaker fees and has attended an advisory board for Lilly; has received speaker fees from Pfizer, Novartis, Roche, and Pierre Fabre; and has attended an advisory board for AstraZeneca. Mireia Margeli Vila has attended an advisory board for Gilead, Lilly, Piere Fabre, Daiichi Sankyo, and Eisai; has received a grant from Pfizer; and has received speaker fees from Pierre Fabre. Fernando Moreno Antón has received speaker fees, grants, and other fees and has attended an advisory board for Pfizer; has attended an advisory board for Novartis, Daiichi Sankyo, and AstraZeneca; and has received other fees from MSD, Pierre Fabre, Gilead, Seagen, and Roche. Sonia Pernas has received speaker fees and non-financial support and has attended an advisory board for AstraZeneca and Daiichi Sankyo; has received grants and has attended an advisory board for Roche; has received speaker fees and non-financial support from Lilly and Novartis; has attended an advisory board for Pierre Fabre and Seagen; has received non-financial support Gilead; has received non-financial support and has attended an advisory board for Pfizer; and has received speaker fees from Eisai. Meritxell Bellet Ezquerra has received speaker fees from Pfizer, Lilly, and Novartis; has attended an advisory board for Pfizer, Lilly, Novartis, and Stemline Menarini; and has received travel expenses from Pfizer. Carmen Hinojo Gonzalez, Teresa Ramon y Cajal, and Nuria Ribelles declare that they have no conflicts of interest. Ethics approval and informed consent: Not applicable. The manuscript does not contain clinical studies or patient data.

References

    1. Sociedad Española de Oncología Médica. Las Cifras Del Cáncer En España, https://seom.org/images/LAS_CIFRAS_DEL_CANCER_EN_ESPANA_2022.pdf ; 2022 [accessed 23 Jun 2025].
    1. Mertz S, Benjamin C, Girvalaki C, Cardone A, Gono P, May SG, et al. Progression-free survival and quality of life in metastatic breast cancer: the patient perspective. Breast. 2022;65:84–90. https://doi.org/10.1016/j.breast.2022.07.006 . - DOI - PubMed - PMC
    1. Lau KH, Tan AM, Shi Y. New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci. 2022;23:2288. https://doi.org/10.3390/ijms23042288 . - DOI - PubMed - PMC
    1. Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE Jr, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis. 1994;18:421. https://doi.org/10.1093/clinids/18.3.421 . - DOI - PubMed
    1. Garcia-Saenz JA, Blancas I, Echavarria I, Hinojo C, Margeli M, Moreno F, et al. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022). Clin Transl Oncol. 2023;25:2665–78. https://doi.org/10.1007/s12094-023-03203-8 . - DOI - PubMed - PMC

LinkOut - more resources